Yang L, Stanworth S, Baglin T
Department of Haematology, Addenbrooke's Hospital, Cambridge, UK.
Transfus Med. 2012 Oct;22(5):315-20. doi: 10.1111/j.1365-3148.2012.01181.x.
Cryoprecipitate is an allogeneic blood product prepared from human plasma. It contains factors VIII, von Willebrand factor (vWF), fibrinogen, fibronectin and factor XIII. Its use was first described in the 1960s for treatment of patients with factor VIII deficiency. It has also been used to treat patients with congenital hypofibrinogenaemia. Now, the most common use of cryoprecipitate is fibrinogen replacement in patients with acquired hypofibrinogenaemia and bleeding. Despite almost 50 years of use, evidence of efficacy is limited. This review provides an overview of the history of cryoprecipitate use, the current debates on the use of this product and future developments.
冷沉淀是一种从人血浆中制备的异体血液制品。它含有凝血因子 VIII、血管性血友病因子（vWF）、纤维蛋白原、纤连蛋白和凝血因子 XIII。其用途最早在 20 世纪 60 年代被描述用于治疗凝血因子 VIII 缺乏症患者。它也被用于治疗先天性低纤维蛋白原血症患者。目前，冷沉淀最常见的用途是在获得性低纤维蛋白原血症和出血患者中替代纤维蛋白原。尽管使用了近 50 年，但其疗效证据有限。本综述概述了冷沉淀的使用历史、关于该产品使用的当前争议以及未来发展。
